Cargando…
AdipoRon and Pancreatic Ductal Adenocarcinoma: a future perspective in overcoming chemotherapy-induced resistance?
The latest scientific knowledge has provided additional insights accountable for the worst prognosis for pancreatic ductal adenocarcinoma (PDAC). Among the causative factors, the aptitude to develop resistance towards approved medications denotes the master key for understanding the lack of improvem...
Autores principales: | Sapio, Luigi, Ragone, Angela, Spina, Annamaria, Salzillo, Alessia, Naviglio, Silvio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
OAE Publishing Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511794/ https://www.ncbi.nlm.nih.gov/pubmed/36176754 http://dx.doi.org/10.20517/cdr.2022.34 |
Ejemplares similares
-
Integrating Gemcitabine-Based Therapy With AdipoRon Enhances Growth Inhibition in Human PDAC Cell Lines
por: Ragone, Angela, et al.
Publicado: (2022) -
AdipoRon and Other Adiponectin Receptor Agonists as Potential Candidates in Cancer Treatments
por: Nigro, Ersilia, et al.
Publicado: (2021) -
AdipoRon Affects Cell Cycle Progression and Inhibits Proliferation in Human Osteosarcoma Cells
por: Sapio, Luigi, et al.
Publicado: (2020) -
AdipoRon may be benefit for atherosclerosis prevention
por: Esfahani, Maryam, et al.
Publicado: (2017) -
Chlorogenic Acid Enhances Doxorubicin-Mediated Cytotoxic Effect in Osteosarcoma Cells
por: Salzillo, Alessia, et al.
Publicado: (2021)